Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kate Newbold

Showing results (51-60 of 72) with videos related to

Pageof 8
Sort By:
European Thyroid Journal|June 20, 2025
Molecular predictive biomarker testing in advanced thyroid cancer - a European consensusAleš Ryška, Jaume Capdevila, Matthias S Dettmer, et al.
International Journal of Radiation Oncology, Biology, Physics|February 6, 2022
Comprehensive Quantitative Evaluation of Variability in Magnetic Resonance-Guided Delineation of Oropharyngeal Gross Tumor Volumes and High-Risk Clinical Target Volumes: An R-IDEAL Stage 0 Prospective StudyCarlos E Cardenas, Sanne E Blinde, Abdallah S R Mohamed, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 10, 2023
Normal organ dosimetry for thyroid cancer patients treated with radioiodine as part of the multi-centre multi-national Horizon 2020 MEDIRAD projectJan Taprogge, Alex Vergara-Gil, Francesca Leek, et al.
Journal for Immunotherapy of Cancer|August 8, 2020
Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancerEva Crespo-Rodriguez, Katharina Bergerhoff, Galabina Bozhanova, et al.
European Thyroid Journal|October 13, 2022
2022 European Thyroid Association Guidelines for the management of pediatric thyroid nodules and differentiated thyroid carcinomaChantal A Lebbink, Thera P Links, Agnieszka Czarniecka, et al.
Radiation Oncology (London, England)|May 15, 2015
Prospective, longitudinal, multi-modal functional imaging for radical chemo-IMRT treatment of locally advanced head and neck cancer: the INSIGHT studyLiam Welsh, Rafal Panek, Dualta McQuaid, et al.
European Thyroid Journal|June 18, 2025
Predictive factors of radioiodine ablation success: results from a MEDIRAD prospective clinical study for thyroid cancerJan Taprogge, Iain Murray, Hannah Sharman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 21, 2010
Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancersKevin J Harrington, Eleni M Karapanagiotou, Victoria Roulstone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 28, 2015
A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid CancerMartin Schlumberger, Barbara Jarzab, Maria E Cabanillas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2021
Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid CancerLori J Wirth, Marcia S Brose, Eric J Sherman, et al.
Pageof 8

Showing results (51-60 of 72) with videos related to

Sort By:
Pageof 8
European Thyroid Journal|June 20, 2025
Molecular predictive biomarker testing in advanced thyroid cancer - a European consensusAleš Ryška, Jaume Capdevila, Matthias S Dettmer, et al.
International Journal of Radiation Oncology, Biology, Physics|February 6, 2022
Comprehensive Quantitative Evaluation of Variability in Magnetic Resonance-Guided Delineation of Oropharyngeal Gross Tumor Volumes and High-Risk Clinical Target Volumes: An R-IDEAL Stage 0 Prospective StudyCarlos E Cardenas, Sanne E Blinde, Abdallah S R Mohamed, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 10, 2023
Normal organ dosimetry for thyroid cancer patients treated with radioiodine as part of the multi-centre multi-national Horizon 2020 MEDIRAD projectJan Taprogge, Alex Vergara-Gil, Francesca Leek, et al.
Journal for Immunotherapy of Cancer|August 8, 2020
Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancerEva Crespo-Rodriguez, Katharina Bergerhoff, Galabina Bozhanova, et al.
European Thyroid Journal|October 13, 2022
2022 European Thyroid Association Guidelines for the management of pediatric thyroid nodules and differentiated thyroid carcinomaChantal A Lebbink, Thera P Links, Agnieszka Czarniecka, et al.
Radiation Oncology (London, England)|May 15, 2015
Prospective, longitudinal, multi-modal functional imaging for radical chemo-IMRT treatment of locally advanced head and neck cancer: the INSIGHT studyLiam Welsh, Rafal Panek, Dualta McQuaid, et al.
European Thyroid Journal|June 18, 2025
Predictive factors of radioiodine ablation success: results from a MEDIRAD prospective clinical study for thyroid cancerJan Taprogge, Iain Murray, Hannah Sharman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 21, 2010
Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancersKevin J Harrington, Eleni M Karapanagiotou, Victoria Roulstone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 28, 2015
A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid CancerMartin Schlumberger, Barbara Jarzab, Maria E Cabanillas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2021
Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid CancerLori J Wirth, Marcia S Brose, Eric J Sherman, et al.
Pageof 8